Shares of ImmuPharma plc (LON:IMM – Get Free Report) were down 31.4% during trading on Monday . The stock traded as low as GBX 6.70 and last traded at GBX 6.70. Approximately 27,337,178 shares traded hands during mid-day trading, an increase of 242% from the average daily volume of 7,982,150 shares. The stock had previously closed at GBX 9.76.
ImmuPharma Price Performance
The company has a 50-day moving average of GBX 10.80 and a two-hundred day moving average of GBX 5.87. The stock has a market capitalization of £37.20 million, a PE ratio of -8.31 and a beta of 1.53.
About ImmuPharma
ImmuPharma PLC (LSE AIM: IMM) is a specialty biopharmaceutical company that discovers and develops peptide-based therapeutics. The Company’s portfolio includes novel peptide therapeutics for autoimmune diseases and anti-infectives. The lead program, P140 (Lupuzor™), is a first-in class autophagy immunomodulator for the treatment of Lupus and preclinical analysis suggest therapeutic activity for many other autoimmune diseases that share the same autophagy mechanism of action.
See Also
- Five stocks we like better than ImmuPharma
- What is a Dividend King?
- Why Gold Loves Trump as Much as Trump Loves Gold
- Growth Investing: Should You Adopt This Investing Strategy in 2022?
- Google’s Gemini 3 Sends Broadcom Soaring: TPUs Take Center Stage
- Best of the list of Dividend Aristocrats: Build wealth with the aristocrat index
- Palantir Isn’t Just Riding the AI Boom—It’s Orchestrating It
Receive News & Ratings for ImmuPharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ImmuPharma and related companies with MarketBeat.com's FREE daily email newsletter.
